Vanguard Group’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $197M | Sell |
8,432,247
-281,273
| -3% | -$6.27M | ﹤0.01% | 1552 |
|
|
2025
Q3 | $172M | Sell |
8,713,520
-52,315
| -0.6% | -$1.08M | ﹤0.01% | 1617 |
|
|
2025
Q2 | $190M | Buy |
8,765,835
+270,255
| +3% | +$6.38M | ﹤0.01% | 1523 |
|
|
2025
Q1 | $206M | Buy |
8,495,580
+64,486
| +0.8% | +$1.45M | ﹤0.01% | 1467 |
|
|
2024
Q4 | $176M | Buy |
8,431,094
+390,116
| +5% | +$8.38M | ﹤0.01% | 1601 |
|
|
2024
Q3 | $160M | Sell |
8,040,978
-59,377
| -0.7% | -$1.1M | ﹤0.01% | 1656 |
|
|
2024
Q2 | $125M | Buy |
8,100,355
+119,694
| +1% | +$1.86M | ﹤0.01% | 1732 |
|
|
2024
Q1 | $127M | Buy |
7,980,661
+860,244
| +12% | +$13M | ﹤0.01% | 1741 |
|
|
2023
Q4 | $120M | Buy |
7,120,417
+73,930
| +1% | +$1.01M | ﹤0.01% | 1767 |
|
|
2023
Q3 | $82.4M | Buy |
7,046,487
+174,739
| +3% | +$2.34M | ﹤0.01% | 1910 |
|
|
2023
Q2 | $92.4M | Sell |
6,871,748
-54,698
| -0.8% | -$787K | ﹤0.01% | 1893 |
|
|
2023
Q1 | $115M | Buy |
6,926,446
+157,705
| +2% | +$2.6M | ﹤0.01% | 1764 |
|
|
2022
Q4 | $126M | Buy |
6,768,741
+629,091
| +10% | +$9.69M | ﹤0.01% | 1675 |
|
|
2022
Q3 | $78.8M | Buy |
6,139,650
+1,277,662
| +26% | +$15.1M | ﹤0.01% | 1936 |
|
|
2022
Q2 | $34.1M | Buy |
4,861,988
+128,384
| +3% | +$942K | ﹤0.01% | 2380 |
|
|
2022
Q1 | $39.2M | Sell |
4,733,604
-102,709
| -2% | -$726K | ﹤0.01% | 2422 |
|
|
2021
Q4 | $32.7M | Sell |
4,836,313
-59,540
| -1% | -$392K | ﹤0.01% | 2579 |
|
|
2021
Q3 | $25.9M | Sell |
4,895,853
-90,369
| -2% | -$494K | ﹤0.01% | 2703 |
|
|
2021
Q2 | $28.7M | Sell |
4,986,222
-600,073
| -11% | -$3.1M | ﹤0.01% | 2654 |
|
|
2021
Q1 | $25.8M | Sell |
5,586,295
-184,784
| -3% | -$734K | ﹤0.01% | 2653 |
|
|
2020
Q4 | $19.3M | Buy |
5,771,079
+822,923
| +17% | +$2.76M | ﹤0.01% | 2647 |
|
|
2020
Q3 | $14.7M | Sell |
4,948,156
-142,204
| -3% | -$556K | ﹤0.01% | 2595 |
|
|
2020
Q2 | $23.5M | Sell |
5,090,360
-53,756
| -1% | -$242K | ﹤0.01% | 2344 |
|
|
2020
Q1 | $19.8M | Buy |
5,144,116
+337,702
| +7% | +$1.39M | ﹤0.01% | 2288 |
|
|
2019
Q4 | $18M | Sell |
4,806,414
-72,934
| -1% | -$341K | ﹤0.01% | 2580 |
|
|
2019
Q3 | $25.9M | Buy |
4,879,348
+17,620
| +0.4% | +$93.9K | ﹤0.01% | 2353 |
|
|
2019
Q2 | $18.7M | Buy |
4,861,728
+95,933
| +2% | +$414K | ﹤0.01% | 2537 |
|
|
2019
Q1 | $24.3M | Sell |
4,765,795
-63,777
| -1% | -$187K | ﹤0.01% | 2414 |
|
|
2018
Q4 | $9.27M | Buy |
4,829,572
+371,421
| +8% | +$1.06M | ﹤0.01% | 2804 |
|
|
2018
Q3 | $16.9M | Buy |
4,458,151
+185,017
| +4% | +$580K | ﹤0.01% | 2659 |
|
|
2018
Q2 | $13.3M | Buy |
4,273,134
+295,227
| +7% | +$896K | ﹤0.01% | 2753 |
|
|
2018
Q1 | $9.51M | Buy |
3,977,907
+336,612
| +9% | +$1.12M | ﹤0.01% | 2849 |
|
|
2017
Q4 | $14.2M | Buy |
3,641,295
+602,872
| +20% | +$1.99M | ﹤0.01% | 2660 |
|
|
2017
Q3 | $7.66M | Sell |
3,038,423
-310,126
| -9% | -$851K | ﹤0.01% | 2944 |
|
|
2017
Q2 | $9.24M | Buy |
3,348,549
+340,614
| +11% | +$711K | ﹤0.01% | 2818 |
|
|
2017
Q1 | $5.87M | Buy |
3,007,935
+15,600
| +0.5% | +$19.9K | ﹤0.01% | 2999 |
|
|
2016
Q4 | $3.14M | Buy |
2,992,335
+82,751
| +3% | +$94.5K | ﹤0.01% | 3207 |
|
|
2016
Q3 | $3.17M | Hold |
2,909,584
| – | – | ﹤0.01% | 3211 |
|
|
2016
Q2 | $2.07M | Sell |
2,909,584
-214,856
| -7% | -$173K | ﹤0.01% | 3370 |
|
|
2016
Q1 | $3.66M | Buy |
3,124,440
+527,611
| +20% | +$818K | ﹤0.01% | 3124 |
|
|
2015
Q4 | $6.36M | Buy |
2,596,829
+65,951
| +3% | +$189K | ﹤0.01% | 2876 |
|
|
2015
Q3 | $7.59M | Buy |
2,530,878
+133,740
| +6% | +$577K | ﹤0.01% | 2753 |
|
|
2015
Q2 | $9.9M | Buy |
2,397,138
+168,549
| +8% | +$672K | ﹤0.01% | 2678 |
|
|
2015
Q1 | $9.65M | Buy |
2,228,589
+280,740
| +14% | +$1.01M | ﹤0.01% | 2665 |
|
|
2014
Q4 | $5.79M | Buy |
1,947,849
+72,400
| +4% | +$199K | ﹤0.01% | 2819 |
|
|
2014
Q3 | $6.23M | Buy |
1,875,449
+86,807
| +5% | +$227K | ﹤0.01% | 2719 |
|
|
2014
Q2 | $4.53M | Buy |
1,788,642
+153,782
| +9% | +$328K | ﹤0.01% | 2886 |
|
|
2014
Q1 | $3.69M | Buy |
1,634,860
+200,742
| +14% | +$420K | ﹤0.01% | 2973 |
|
|
2013
Q4 | $2.8M | Buy |
1,434,118
+239,800
| +20% | +$485K | ﹤0.01% | 3056 |
|
|
2013
Q3 | $3.64M | Buy |
1,194,318
+638,733
| +115% | +$1.07M | ﹤0.01% | 2899 |
|
|
2013
Q2 | $494K | Buy |
+555,585
| New | +$445K | ﹤0.01% | 3484 |
|
Other funds holding CPRX
DM
Vanguard Group's CPRX Position: Q4 2025 in Review
Vanguard Group reduced its Catalyst Pharmaceutical (CPRX) stake by 3.2% in Q4 2025, selling an estimated $6.27M and leaving 8,432,247 shares worth $197M. The position accounts for ﹤0.01% of the portfolio, ranked #1552.
Vanguard Group first reported a position in CPRX in Q2 2013 and has held it in 51 quarters since. The position peaked at $206M in Q1 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.
- Vanguard Group held 8,432,247 shares of Catalyst Pharmaceutical worth $197M as of Q4 2025.
- Vanguard Group sold 281,273 Catalyst Pharmaceutical shares in Q4 2025, an estimated $6.27M.
- Catalyst Pharmaceutical made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1552 holding.
- Vanguard Group first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Catalyst Pharmaceutical position peaked at $206M in Q1 2025.
- 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.